logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin us
 

News

boto imprimir
Date: 13/12/2016

CaixaImpulse funds an IDIBELL project on hospital-acquired infections


An innovative project on the prevention of hospital-acquired infections developed at Bellvitge Biomedical Research Institute (IDIBELL) has been selected by Caixaimpulse, the first comprehensive programme in Spain for the creation of biotechnology companies, to receive financial support of up to 70,000 euros as well as a comprehensive programme of training and expert advice. The project, lead by Dr. Rafael Máñez, aims to establish a new treatment to prevent nosocomial infections, which will improve patient survival along with reducing hospital stays and associated costs.

 

Removal of antibodies with glycoconjugates


It is estimated that hospital-acquired or nocosomial infections are one of the leading causes of mortality both in Europe and the United States, affecting 10% of admitted patients. Gram-negative bacteria account for the vast majority of infections, and are associated with severe clinical conditions such as sepsis and septic shock.

 

Antibody-dependent enhancement (ADE) of infection occurs when pre-exisiting non-neutralizing antibodies bind to a pathogen, facilitating infection instead of dampening it. The unique and novel approach developed by Dr. Mánez’s research group aims to boost immunity in these patients by deactivating non-neutralizing antibodies with glycoconjugates, thus priming neutralizing antibodies.  This selective depletion of ADE antibodies by glycoconjugates will improve serum bactericidal activity and prevents mortality in experimental Gram-negative infections.

 

The use of glycoconjugates to boost immunity is a unique novel approach both for its mechanism of action and effect, which could become a very effective therapy to fight infections by Gram-negative. The possibility of boosting immunity by only depleting the non-neutralizing antibodies in the body represents a radical innovation as a therapeutic approach, which could also be used in other infections and cancer.

 

Valuation and commercialisation, pending challenges


According to the Innovation Union Scoreboard 2016 (IUS) report, Spain has cutting-edge infrastructure, first-rate research centres, and professionals.  Nevertheless, it is ranked 21st in the European Union (EU) for innovation.

 

In order to help change this reality, Obra Social ”la Caixa” and Caixa Capital Risc launched CaixaImpulse, which uses their expertise in the fields of research, creation, development and investment in early-stage companies for a common aim: the transfer of research results to society.

 

Jordi Portabella, Director of Research and Knowledge at the ”la Caixa” Banking Foundation, and Carlos Trenchs, Managing Director at Caixa Capital Risc, presented all the selected innovative proposals yesterday.  Of the 73 projects that were initially submitted, a committee of experts have chosen the 20 finalists, 3 of which belong to the field of life sciences, while 17 belong to the medical sciences and healthcare sectors.





foto CaixaImpulse selected participants at Palau Macaya
CaixaImpulse selected participants at Palau Macaya

Share/Bookmark
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell